Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention

References

• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med.60(2), 221–225 (1976).
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol.145(5), 408–415 (1997).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J. Rheumatol.14(Suppl. 13), S223–S226 (1987).
   Web of Science ®Google Scholar
• Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am. J. Med.93(5), 513–519 (1992).
   PubMed Web of Science ®Google Scholar
• Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore)68(3), 141–150 (1989).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349(25), 2399–2406 (2003).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Crow MK, Lockshin MD et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.56(10), 3412–3419 (2007).
   PubMed Web of Science ®Google Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum.42(1), 51–60 (1999).
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349(25), 2407–2415 (2003).
   PubMed Web of Science ®Google Scholar
• El-Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation110(4), 399–404 (2004).
   PubMed Web of Science ®Google Scholar
• Salel AF, Fong A, Zelis BS, Miller RR, Borhani NO, Mason DT. Accuracy of numerical coronary profile. Correlation of risk factors with arteriographically documented severity of atherosclerosis. N. Engl. J. Med.296(25), 1447–1450 (1977).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.44(10), 2331–2337 (2001).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis. Chest56(1), 43–52 (1969).
   PubMedGoogle Scholar
• Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum.48(11), 3159–3167 (2003).
   PubMed Web of Science ®Google Scholar
• Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford)43(7), 924–929 (2004).
   PubMed Web of Science ®Google Scholar
• Von Feldt JM, Scalzi LV, Cucchiara AJ et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum.54(7), 2220–2227 (2006).
   PubMed Web of Science ®Google Scholar
• Drueke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat. Rev. Nephrol.6(12), 723–735 (2010).
   PubMed Web of Science ®Google Scholar
• Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus16(1), 28–34 (2007).
   PubMed Web of Science ®Google Scholar
• Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J. Rheumatol.21(7), 1264–1267 (1994).
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin. Nephrol.23(4), 406–411 (2003).
   PubMed Web of Science ®Google Scholar
• Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int.44(3), 638–642 (1993).
   PubMed Web of Science ®Google Scholar
• Theodoridou A, Bento L, D’Cruz DP, Khamashta MA, Hughes GR. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann. Rheum. Dis.62(12), 1199–1203 (2003).
   PubMed Web of Science ®Google Scholar
• Manger K, Kusus M, Forster C et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann. Rheum. Dis.62(9), 846–850 (2003).
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis.62(11), 1071–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald SG et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum.50(1), 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Schanberg LE, Sandborg C, Barnhart HX et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum.60(5), 1496–1507 (2009).
   PubMed Web of Science ®Google Scholar
• McMahon M, Grossman J, Skaggs B et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum.60(8), 2428–2437 (2009).
   PubMed Web of Science ®Google Scholar
• Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus9(3), 170–175 (2000).
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation104(16), 1887–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352(16), 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340(2), 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol.21(12), 1876–1890 (2001).
   PubMed Web of Science ®Google Scholar
• Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest.90(3), 1138–1144 (1992).
   PubMed Web of Science ®Google Scholar
• Watson AD, Leitinger N, Navab M et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem.272(21), 13597–13607 (1997).
   PubMed Web of Science ®Google Scholar
• Calabresi L, Franceschini G, Sirtori CR et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun.238(1), 61–65 (1997).
   PubMed Web of Science ®Google Scholar
• Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol.15(11), 1987–1994 (1995).
   PubMed Web of Science ®Google Scholar
• Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest.102(1), 145–152 (1998).
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis170(2), 191–203 (2003).
   PubMed Web of Science ®Google Scholar
• Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J. Leukoc. Biol.78(4), 805–818 (2005).
   PubMed Web of Science ®Google Scholar
• Wang JM, Sica A, Peri G et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler. Thromb.11(5), 1166–1174 (1991).
   PubMed Web of Science ®Google Scholar
• Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler. Thromb. Vasc. Biol.16(5), 673–677 (1996).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol.13(3), 285–288 (2002).
   PubMed Web of Science ®Google Scholar
• Larsson PT, Hallerstam S, Rosfors S, Wallen NH. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int. Angiol.24(1), 43–51 (2005).
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell2(2), 275–281 (1998).
   PubMed Web of Science ®Google Scholar
• Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G. Identification of apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis8(4), 368–377 (1988).
   PubMedGoogle Scholar
• Navab M, Hama SY, Cooke CJ et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res.41(9), 1481–1494 (2000).
   PubMed Web of Science ®Google Scholar
• Navab M, Berliner JA, Watson AD et al. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol.16(7), 831–842 (1996).
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med.353(1), 46–57 (2005).
   PubMed Web of Science ®Google Scholar
• Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet341(8850), 923–925 (1993).
   PubMed Web of Science ®Google Scholar
• Aho K, Vaarala O, Tenkanen L et al. Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol.14(5), 499–506 (1996).
   PubMed Web of Science ®Google Scholar
• Romero FI, Amengual O, Atsumi T, Khamashta MA, Tinahones FJ, Hughes GR. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-β2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol.37(8), 883–888 (1998).
   PubMedGoogle Scholar
• Hayem G, Nicaise-Roland P, Palazzo E et al. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus10(5), 346–351 (2001).
   PubMed Web of Science ®Google Scholar
• Gomez-Zumaquero JM, Tinahones FJ, De Ramon E, Camps M, Garrido L, Soriguer FJ. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford)43(4), 510–513 (2004).
   PubMed Web of Science ®Google Scholar
• Navab M, Fogelman AM, Berliner JA et al. Pathogenesis of atherosclerosis. Am. J. Cardiol.76(9), 18C–23C (1995).
   PubMed Web of Science ®Google Scholar
• Podrez EA, Poliakov E, Shen Z et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem.277(41), 38517–38523 (2002).
   PubMed Web of Science ®Google Scholar
• Podrez EA, Poliakov E, Shen Z et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem.277(41), 38503–38516 (2002).
   PubMed Web of Science ®Google Scholar
• Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost.78(1), 195–199 (1997).
   PubMed Web of Science ®Google Scholar
• Remaley AT, Thomas F, Stonik JA et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res.44(4), 828–836 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation108(6), 661–663 (2003).
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta, 1044(2), 275–283 (1990).
   PubMed Web of Science ®Google Scholar
• Ohta T, Takata K, Horiuchi S, Morino Y, Matsuda I. Protective effect of lipoproteins containing apoprotein A-I on Cu2+-catalyzed oxidation of human low density lipoprotein. FEBS Lett.257(2), 435–438 (1989).
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest.96(6), 2882–2891 (1995).
   PubMed Web of Science ®Google Scholar
• Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res.41(9), 1495–1508 (2000).
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis145(1), 33–43 (1999).
   PubMed Web of Science ®Google Scholar
• Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest.97(9), 2130–2138 (1996).
   PubMed Web of Science ®Google Scholar
• Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation112(7), 1054–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. γ-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ. Res.63(4), 712–719 (1988).
   PubMed Web of Science ®Google Scholar
• Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-γ induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J. Biol. Chem.275(30), 22895–22904 (2000).
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol.21, 713–758 (2003).
   PubMed Web of Science ®Google Scholar
• Whitman SC, Ravisankar P, Daugherty A. IFN-γ deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J. Interferon Cytokine Res.22(6), 661–670 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-γ potentiates atherosclerosis in apoE knock-out mice. J. Clin. Invest.99(11), 2752–2761 (1997).
   PubMed Web of Science ®Google Scholar
• Fernandes JL, Mamoni RL, Orford JL et al. Increased Th1 activity in patients with coronary artery disease. Cytokine26(3), 131–137 (2004).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res.95(8), 764–772 (2004).
   PubMed Web of Science ®Google Scholar
• Saren P, Welgus HG, Kovanen PT. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol.157(9), 4159–4165 (1996).
   PubMed Web of Science ®Google Scholar
• Wadham C, Albanese N, Roberts J et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation109(17), 2116–2122 (2004).
   PubMed Web of Science ®Google Scholar
• Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J. Biol. Chem.262(17), 8390–8394 (1987).
   PubMed Web of Science ®Google Scholar
• Ehnholm C, Aho K, Huttunen JK et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis2(1), 68–73 (1982).
   PubMedGoogle Scholar
• Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis99(2), 241–252 (1993).
   PubMed Web of Science ®Google Scholar
• Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol.24(11), 2137–2142 (2004).
   PubMed Web of Science ®Google Scholar
• Barath P, Cao J, Forrester JS. Low density lipoprotein activates monocytes to express tumor necrosis factor. FEBS Lett.277(1–2), 180–184 (1990).
   PubMed Web of Science ®Google Scholar
• Haddy N, Sass C, Droesch S et al. IL-6, TNF-α and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis170(2), 277–283 (2003).
   PubMed Web of Science ®Google Scholar
• Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis172(2), 299–308 (2004).
   PubMed Web of Science ®Google Scholar
• Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA286(17), 2107–2113 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation103(13), 1813–1818 (2001).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation103(21), 2531–2534 (2001).
   PubMed Web of Science ®Google Scholar
• Rovere P, Peri G, Fazzini F et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood96(13), 4300–4306 (2000).
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation103(18), 2283–2288 (2001).
   PubMed Web of Science ®Google Scholar
• Biasucci LM, Vitelli A, Liuzzo G et al. Elevated levels of interleukin-6 in unstable angina. Circulation94(5), 874–877 (1996).
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med.331(7), 417–424 (1994).
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther.7(3), R634–R643 (2005).
   PubMed Web of Science ®Google Scholar
• George J, Harats D, Gilburd B et al. Adoptive transfer of β2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation102(15), 1822–1827 (2000).
   PubMed Web of Science ®Google Scholar
• George J, Yacov N, Breitbart E et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with β 2-glycoprotein I. Cardiovasc. Res.62(3), 603–609 (2004).
   PubMed Web of Science ®Google Scholar
• Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol.18(12), 1972–1982 (1998).
   PubMed Web of Science ®Google Scholar
• Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum.48(10), 2974–2978 (2003).
   PubMed Web of Science ®Google Scholar
• Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann. Rheum. Dis.64(2), 315–317 (2005).
   PubMed Web of Science ®Google Scholar
• Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol.17(11), 3159–3163 (1997).
   PubMed Web of Science ®Google Scholar
• Vaarala O, Manttari M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation91(1), 23–27 (1995).
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bourrinet E, Motte G, Chalopin JM. Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. Kidney Int.64(3), 1065–1070 (2003).
   PubMed Web of Science ®Google Scholar
• Toloza SM, Uribe AG, McGwin G Jr et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum.50(12), 3947–3957 (2004).
   PubMed Web of Science ®Google Scholar
• Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb. Res.114(5–6), 593–595 (2004).
   PubMed Web of Science ®Google Scholar
• Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin. Immunol.112(2), 169–174 (2004).
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. The role of innate immunity in the induction of autoimmunity. Autoimmun. Rev.8(1), 69–72 (2008).
   PubMed Web of Science ®Google Scholar
• Campbell LA, Yaraei K, Van Lenten B et al. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microbes Infect.12(8–9), 598–606 (2010).
   PubMed Web of Science ®Google Scholar
• Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem.278(3), 1561–1568 (2003).
   PubMed Web of Science ®Google Scholar
• Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity43(1), 76–83 (2010).
   PubMed Web of Science ®Google Scholar
• Denny MF, Thacker S, Mehta H et al. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood110(8), 2907–2915 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PY, Li Y, Richards HB et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum.56(11), 3759–3769 (2007).
   PubMed Web of Science ®Google Scholar
• Park YB, Lee SK, Lee WK et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol.26(8), 1701–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford)42(7), 893–899 (2003).
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Reber G, James R et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J. Autoimmun.23(4), 353–360 (2004).
   PubMed Web of Science ®Google Scholar
• Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus7(5), 355–360 (1998).
   PubMed Web of Science ®Google Scholar
• O’Neill SG, Giles I, Lambrianides A et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum.62(3), 845–854 (2010).
   PubMed Web of Science ®Google Scholar
• Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation87(4), 1107–1113 (1993).
   PubMed Web of Science ®Google Scholar
• Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb. Res.18(1–2), 113–121 (1980).
   PubMed Web of Science ®Google Scholar
• Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J. Clin. Invest.91(6), 2873–2879 (1993).
   PubMed Web of Science ®Google Scholar
• Upchurch GR Jr, Welch GN, Fabian AJ et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J. Biol. Chem.272(27), 17012–17017 (1997).
   PubMed Web of Science ®Google Scholar
• Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation103(22), 2717–2723 (2001).
   PubMed Web of Science ®Google Scholar
• McCully KS. Homocysteine and vascular disease. Nat. Med.2(4), 386–389 (1996).
   PubMed Web of Science ®Google Scholar
• Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest.91(1), 308–318 (1993).
   PubMed Web of Science ®Google Scholar
• Woo KS, Chook P, Lolin YI et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation96(8), 2542–2544 (1997).
   PubMed Web of Science ®Google Scholar
• Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin. Rheumatol.21(6), 457–461 (2002).
   PubMed Web of Science ®Google Scholar
• Otero M, Lago R, Gomez R et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford)45(8), 944–950 (2006).
   PubMed Web of Science ®Google Scholar
• Bjorbaek C, Elmquist JK, Michl P et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology139(8), 3485–3491 (1998).
   PubMed Web of Science ®Google Scholar
• Beltowski J. Leptin and atherosclerosis. Atherosclerosis189(1), 47–60 (2006).
   PubMed Web of Science ®Google Scholar
• Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J. Hypertens.24(5), 789–801 (2006).
   PubMed Web of Science ®Google Scholar
• Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J.13(10), 1231–1238 (1999).
   PubMed Web of Science ®Google Scholar
• Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension47(2), 222–229 (2006).
   PubMed Web of Science ®Google Scholar
• Porreca E, Di Febbo C, Moretta V et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis175(1), 139–143 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol. Int.22(4), 138–141 (2002).
   PubMed Web of Science ®Google Scholar
• Wislowska M, Rok M, Stepien K, Kuklo-Kowalska A. Serum leptin in systemic lupus erythematosus. Rheumatol. Int.28(5), 467–473 (2008).
   PubMed Web of Science ®Google Scholar
• Sada KE, Yamasaki Y, Maruyama M et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J. Rheumatol.33(8), 1545–1552 (2006).
   PubMed Web of Science ®Google Scholar
• Al M, Ng L, Tyrrell P, Bargman J, Bradley T, Silverman E. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford)48(5), 497–501 (2009).
   PubMed Web of Science ®Google Scholar
• Otero M, Lago R, Gomez R et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis.65(9), 1198–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson PD, Mehta NN, Wolfe ML et al. Innate immunity modulates adipokines in humans. J. Clin. Endocrinol. Metab.92(6), 2272–2279 (2007).
   PubMed Web of Science ®Google Scholar
• McMahon M, Anderson M, Grossman J et al. Plasma leptin levels are associated with carotid artery plaque and intima-media thickness (IMT) in women with SLE and a matched population of healthy women. Arthritis Rheum.56, S796 (2007).
   Google Scholar
• Reynolds HR, Buyon J, Kim M et al. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis210(2), 569–574 (2010).
   PubMed Web of Science ®Google Scholar
• Chung C, Long A, Solus J et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus18(9), 799–806 (2009).
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest.96(6), 2758–2767 (1995).
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med.340(6), 448–454 (1999).
   PubMed Web of Science ®Google Scholar
• McMahon M, Grossman J, Fitzgerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum.54(8), 2541–2549 (2006).
   PubMed Web of Science ®Google Scholar
• Bruce IN. ‘Not only...but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford)44(12), 1492–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Homer D, Ingall TJ, Baker HL Jr, O’Fallon WM, Kottke BA, Whisnant JP. Serum lipids and lipoproteins are less powerful predictors of extracranial carotid artery atherosclerosis than are cigarette smoking and hypertension. Mayo Clin. Proc.66(3), 259–267 (1991).
   PubMed Web of Science ®Google Scholar
• Whisnant JP, Homer D, Ingall TJ, Baker HL Jr, O’Fallon WM, Wievers DO. Duration of cigarette smoking is the strongest predictor of severe extracranial carotid artery atherosclerosis. Stroke21(5), 707–714 (1990).
   PubMed Web of Science ®Google Scholar
• Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus – proposed guidelines for risk factor management. Rheumatology (Oxford)43(1), 7–12 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature343(6257), 425–430 (1990).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler. Suppl.5(3), S91–S97 (2004).
   PubMedGoogle Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279(20), 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Chen CH, Jiang W, Via DP et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation101(2), 171–177 (2000).
   PubMed Web of Science ®Google Scholar
• Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol.170(3), 1524–1530 (2003).
   PubMed Web of Science ®Google Scholar
• Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin. Chim. Acta.338(1–2), 17–24 (2003).
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med.197(6), 725–733 (2003).
   PubMed Web of Science ®Google Scholar
• Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature420(6911), 78–84 (2002).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology59(7), 990–997 (2002).
   PubMed Web of Science ®Google Scholar
• Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ. Res.93(10), 948–956 (2003).
   PubMed Web of Science ®Google Scholar
• Cherfan P, Tompa A, Wikby A, Lofgren S, Jonasson L. Effects of simvastatin on human T cells in vivo. Atherosclerosis193(1), 186–192 (2007).
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med.6(12), 1399–1402 (2000).
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-γ induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly131(3–4), 41–46 (2001).
   PubMed Web of Science ®Google Scholar
• Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT, Ledet T. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J.360(Pt 2), 363–370 (2001).
   PubMed Web of Science ®Google Scholar
• Chung HK, Lee IK, Kang H et al. Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med.34(6), 451–461 (2002).
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Gerdes N, Varo N et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation106(23), 2888–2893 (2002).
   PubMed Web of Science ®Google Scholar
• Salonen R, Nyyssonen K, Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation92(7), 1758–1764 (1995).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Haruna Y, Morita Y, Yada T, Satoh M, Fox DA, Kashihara N. Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum.56(6), 1827–1835 (2007).
   PubMed Web of Science ®Google Scholar
• Aprahamian T, Bonegio R, Rizzo J et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol.177(5), 3028–3034 (2006).
   PubMed Web of Science ®Google Scholar
• Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford)46(10), 1560–1565 (2007).
   PubMed Web of Science ®Google Scholar
• Petri M, Kiani A, Post W, Madger L. Lupus atherosclerosis prevention study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum.54(9), S520 (2006).
   Google Scholar
• Norby GE, Holme I, Fellstrom B et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum.60(4), 1060–1064 (2009).
   PubMed Web of Science ®Google Scholar
• Kang S, Wu Y, Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis177(2), 433–442 (2004).
   PubMed Web of Science ®Google Scholar
• Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III Update: adjustments and options. Am. J. Cardiol.96(4A), 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford)47(7), 1093–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Karlson EW, Gall V et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum.53(5), 718–723 (2005).
   PubMed Web of Science ®Google Scholar
• Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J. Biol. Chem.259(13), 8156–8162 (1984).
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension37(4), 1075–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol.26(2), 325–330 (1999).
   PubMed Web of Science ®Google Scholar
• Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus5(Suppl. 1), S16–S22 (1996).
   PubMedGoogle Scholar
• Bevan AP, Krook A, Tikerpae J, Seabright PJ, Siddle K, Smith GD. Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes. J. Biol. Chem.272(43), 26833–26840 (1997).
   PubMed Web of Science ®Google Scholar
• Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation96(12), 4380–4384 (1997).
   PubMed Web of Science ®Google Scholar
• Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost.87(3), 518–522 (2002).
   PubMed Web of Science ®Google Scholar
• Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum.30(12), 1435–1436 (1987).
   PubMed Web of Science ®Google Scholar
• Jung H, Bobba R, Su J et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum.62(3), 863–868 (2010).
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus15(9), 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis.68(2), 238–241 (2009).
   PubMed Web of Science ®Google Scholar
• Alarcon GS, McGwin G, Bertoli AM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis.66(9), 1168–1172 (2007).
   PubMed Web of Science ®Google Scholar
• Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets6(4), 223–235 (2007).
   PubMedGoogle Scholar
• Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest.109(6), 745–753 (2002).
   PubMed Web of Science ®Google Scholar
• Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol.22(11), 1892–1898 (2002).
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Herbin O, Bouaziz JD et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med.207(8), 1579–1587 (2010).
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Lu TY, Fontanillo MF, del Campo-Perez V, Rahman A, Isenberg DA. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology (Oxford)49(4), 691–696 (2010).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation109(25), 3215–3220 (2004).
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Banquerigo ML, Hama S et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol.127(2), 234–244 (2008).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.25(9), 1932–1937 (2005).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Hama S et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.25(7), 1426–1432 (2005).
   PubMed Web of Science ®Google Scholar
• Bloedon LT, Dunbar R, Duffy D et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res.49(6), 1344–1352 (2008).
   PubMed Web of Science ®Google Scholar
• Woo JM, Lin Z, Navab M et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res. Ther.12(3), R93 (2010).
   Google Scholar
• Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNF-α production. Clin. Immunol.137(1), 147–156 (2010).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin. Lymphoma Myeloma8(Suppl. 3), S82–S88 (2008).
   Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12(8), 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? Ann. Rheum. Dis.66(6), 836 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Sitges M, Garcia-Albeniz X, Sionis A, Loma-Osorio P, Bosch X. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. Int. J. Cardiol.139(2), e29–e31 (2010).
   Google Scholar
• Wolf A, Couttet P, Dong M et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk. Res.34(9), 1180–1188 (2010).
   PubMed Web of Science ®Google Scholar
• Yazdany J, Panopalis P, Gillis JZ et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum.61(3), 370–377 (2009).
   PubMed Web of Science ®Google Scholar
• Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH. Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. Semin Arthritis Rheum.40(3), 193–200 (2010).
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibanez D et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum.59(2), 176–180 (2008).
   PubMed Web of Science ®Google Scholar
• Wolak T, Todosoui E, Szendro G et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J. Rheumatol.31(5), 909–914 (2004).
   PubMed Web of Science ®Google Scholar
• Gustafsson J, Gunnarsson I, Borjesson O et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus – a prospective cohort study. Arthritis Res. Ther.11(6), R186 (2009).
   PubMed Web of Science ®Google Scholar
• Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J. Rheumatol.35(7), 1300–1306 (2008).
   PubMed Web of Science ®Google Scholar